Navigation Links
Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes
Date:3/28/2011

EMERYVILLE, Calif., March 28, 2011 /PRNewswire/ -- Bionovo, Inc. (Nasdaq: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that enrollment has started for the Phase 1 clinical trial testing the safety of two doses of Menerba in postmenopausal women for the treatment of menopausal hot flushes (study # MF101-008), also known as "menopausal hot flashes."

This Phase 1, open-label, randomized, clinical trial of Menerba will be conducted at three clinical sites in Northern California. Forty postmenopausal women between the ages of 40 and 65 years will be randomized to one of two doses of Menerba and treated for 28 days. The primary goal of this study is to assess the safety of two doses of MF101 after 4 weeks of treatment. Dr. Wulf Utian will serve as the Principal Investigator for this study.

"We are pleased to announce that we are initiating the Phase 1 tolerability clinical trial. We are confident that the trial will proceed quickly and successfully. We are diligently executing on all our milestones, clinical and non-clinical activities, in 2011," commented Dr. Isaac Cohen, Chairman and Chief Executive Officer of Bionovo, Inc.

"This Phase 1 clinical trial is testing two doses of Menerba that are higher than the already proven efficacious dose evaluated in our Phase 2 trial, which showed efficacy equivalent to recently approved low dose menopausal hormone therapy (MHT). We are escalating the dose of Menerba to reach similar efficacy as the high doses of MHT. Our goal is to define a full therapeutic window that matches or improves on currently approved MHT drugs," said Mary Tagliaferri, M.D., Bionovo's President and Chief Medical Officer.

IRB approval has been granted at the two sites below, and enrollment will commence forthwith: 1.
Clinical Trials Re
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bionovo Announces 2010 Highlights and Year-End Financial Results
2. Bionovo, Inc. to Announce Fourth Quarter Fiscal Year 2010 Financial Results on Tuesday, March 15, 2011
3. Bionovo to Present at the Cowen and Company 31st Annual Healthcare Conference
4. Bionovo Announces 2011 Plan of Action on MF101 (Menerba™)
5. Bionovo Announces Pricing of Follow-on Offering of Common Stock and Warrants
6. Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors
7. Bionovo Releases FDA-Approved Clinical Development Plan for Menerba
8. Bionovo Announces Publication Describing Estrogen Receptor Beta Cancer Prevention Mechanism
9. Bionovo Announces Third Quarter 2010 Highlights and Financial Results
10. Bionovo, Inc. to Announce Third Quarter Fiscal Year 2010 Financial Results on Thursday, November 11, 2010
11. Bionovo Announces Publication Describing Potential Estrogen Receptor Modulating Drugs for Treating Menopausal Conditions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Tasly Pharmaceuticals, Inc., the world,s ... announced today the launch of Deepure. ... address men and women concerned with supporting their ... old age while helping keep their health care ... and herb-based formulas, namely, ProHeart PLUS, ImmunoPower PLUS, ...
(Date:9/30/2014)... 2014  Decision Resources Group finds that the markets ... , Russia , ... (BRIC) will see robust expansion as these economies expand ... procedures. Although revenues will be somewhat impeded by poor ... approval times and demand for low-cost products, the market ...
(Date:9/30/2014)... --  Easy Breathe , the fastest growing online ... now offers the revolutionary AirSense CPAPs by ... apnea therapy devices with internal cellular modems.  This break-through ... share real-time data on each user,s quality of sleep ... addition, the internal modem allows the CPAP to be ...
Breaking Medicine Technology:Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... startup  PhotOral™  announced today it has licensed a ... to develop a novel intraoral device that uses ... dental plaque microorganisms. The agreement empowers ... the $7 billion oral care market.  PhotOral Founder ...
... R.I., Dec. 15, 2011  CVS Caremark announced today ... Chain Distinction Award North America in the Logistics ... week at the annual Supply Chain Logistics Summit ... http://photos.prnewswire.com/prnh/20090226/NE75914LOGO ) The Logistics Best ...
Cached Medicine Technology:Life Sciences Startup PhotOral Licenses Patented Oral Blue-Light Technology From Forsyth Institute 2CVS Caremark Receives Logistics Best Practice Award at 2011 Supply Chain Logistics Summit 2CVS Caremark Receives Logistics Best Practice Award at 2011 Supply Chain Logistics Summit 3
(Date:9/30/2014)... A new study of 58 women conducted ... stress on metabolism after eating a high-fat meal equivalent to ... food restaurant, about 930 calories and 60 grams of fat. ... hour for 7 hours, conducting the study twice on each ... a stressful event in their lives during the previous 24 ...
(Date:9/30/2014)... 2014(BRONX, NY)Medications are the leading cause of allergy-related sudden ... death certificates from 1999 to 2010, conducted by researchers ... Albert Einstein College of Medicine of Yeshiva University . ... of Allergy and Clinical Immunology , also found that ... high among older people and African-Americans and that such ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... is helping people perform better in and out of the ... and memory has caught the attention of Shane Michaels, prompting ... day-to-day grind, fatigue is the reason most people simply just ... whether that means staying focused at work, getting the motivation ...
(Date:9/30/2014)... 2014 With the flu season ... every day, it’s a perfect time to announce ... system is an electro-static disinfectant delivery system that ... normally missed with spray-on disinfectant applicators. , The ... an electrostatic negative charge to the disinfecting solution. ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Bifidobacteria, the ... with age, poor diet, and stress, so a high ... Each capsule of Ultimate Flora™ Men’s Complete ... cultures from 7 Bifidobacteria strains to support a healthy ... to build up, and 32 billion cultures from 7 ...
Breaking Medicine News(10 mins):Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 2Health News:NutriGold Urges Every Woman To Read a Recent Study About Diet and Stress 3Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:Columbus Janitorial Company Announces New Disinfecting System for your workplace 2Health News:ReNew Life Introduces Ultimate Flora™ Men’s Complete Probiotic 90 Billion—Comprehensive Probiotic Support Just for Men 2
... small Gram-negative spiral rods. Campylobacter jejuni ( ... water, milk and meat, especially chicken, is one of ... its mode of pathogenesis is not clear. , A ... in the World Journal of Gastroenterology addresses ...
... China Medical Technologies,Inc. (the "Company") (Nasdaq: ... device,company that develops, manufactures and markets advanced ... has completed the previously,announced sale of its ... (the "HIFU Business") to Chengxuan International Ltd. ...
... 30 Cardium Therapeutics,(NYSE Alternext US: CXM) reported ... indicating that the company is currently considered to ... Alternext US LLC,(formerly the American Stock Exchange). ... which was filed on November 10, 2008, noncompliance ...
... CAMBRIDGE, Mass., Dec. 30 Biopure Corporation (Nasdaq: ... has advised the U.S. Naval Medical Research Center ("NMRC") by ... Biopure,s product Hemopure [hemoglobin glutamer - 250 (bovine)], under a ... As previously announced, the Navy had filed a protocol ...
... repair genes initially appeared to be statistically significantly associated ... from individual studies are pooled, however, few DNA repair ... according to a field synopsis published in the December ... National Cancer Institute. , Because DNA damage is ...
... WLP ) will,release fourth quarter 2008 financial results ... Management will review these results and its,outlook during a conference ... should be accessed at least 15 minutes prior to its ... (Domestic) ...
Cached Medicine News:Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 2Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 3Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 4Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 5Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 2Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 3Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 4Health News:Cardium Reports on Exchange Listing With NYSE Alternext US 5Health News:U.S. Navy Requested Operations Trial on FDA Hold 2Health News:U.S. Navy Requested Operations Trial on FDA Hold 3Health News:Few DNA repair genes maintain association with cancer in field synopsis 2Health News:WellPoint to Hold Conference Call and Webcast to Discuss Fourth Quarter Results on January 28, 2009 2